William Guyer Sells 16,300 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Posted by Francis Steltz on Aug 12th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider William Guyer sold 16,300 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $113.43, for a total value of $1,848,909.00. Following the completion of the sale, the insider directly owned 3,985 shares of the company’s stock, valued at $452,018.55. This trade represents a 80.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

William Guyer also recently made the following trade(s):

On Tuesday, August 4th, William Guyer sold 3,700 shares of Corcept Therapeutics stock. The shares were sold at an average price of $113.12, for a total transaction of $418,544.00.
On Tuesday, July 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $93.13, for a total transaction of $1,862,600.00.
On Tuesday, June 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.60, for a total transaction of $1,412,000.00.

Corcept Therapeutics Trading Up 0.3%

CORT stock traded up $0.32 during trading on Wednesday, reaching $112.18. 648,478 shares of the stock were exchanged, compared to its average volume of 1,572,994. The firm has a market capitalization of $12.13 billion, a price-to-earnings ratio of 267.10 and a beta of 0.45. The business has a 50 day moving average price of $91.00 and a 200-day moving average price of $60.63. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $122.21.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The business had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. During the same quarter last year, the firm earned $0.29 EPS. The business’s revenue was up 31.7% compared to the same quarter last year. On average, research analysts anticipate that Corcept Therapeutics Incorporated will post 1.13 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and issued a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research report on Monday, July 27th. Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. Finally, Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.17.

Get Our Latest Research Report on CORT

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Corcept Therapeutics during the 2nd quarter worth about $1,080,964,000. Parallel Advisors LLC grew its position in Corcept Therapeutics by 2.5% in the 1st quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after acquiring an additional 96,763 shares in the last quarter. State Street Corp increased its stake in Corcept Therapeutics by 0.5% during the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock worth $103,915,000 after purchasing an additional 15,656 shares during the period. Geode Capital Management LLC increased its stake in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.